BibTex RIS Kaynak Göster

Evaluation of Colistin Nephrotoxicity in Intensive Care Diseases of Patient

Yıl 2018, Cilt: 7 Sayı: 1, 10 - 14, 01.01.2018

Fatma Kaplan Efe Fatma Ayerden Ebinç Serdar Karakaya İbrahim Karadağ Murat Eser Oktay Ünsal Aysun Aybal Kutlugün Esin Beyan

https://doi.org/10.5505/abantmedj.2018.39306

Öz

INTRODUCTION: Evaluation of the development of nephrotoxicity and the factors affecting it in patients treated with colistin theraphMETHODS: 51 patients who received colistin treatment were divided into two groups as nephrotoxicity developing and nondeveloping. Demographic and laboratory data between the groups were comparedRESULTS: Colistin induced nephrotoxicity was detected in 64.7% of the patients. Patients who developed nephrotoxicity had a higher mortality rate p: 0.01 .DISCUSSION AND CONCLUSION: Nephrotoxicity of colistin should be noted in ICU patients.

Anahtar Kelimeler

Colistin nephrotoxicity intensive care unit

Kaynakça

  • Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005 May 1;40(9):1333-41.
  • Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther.2012 Aug;10(8):917-34.
  • Pike M, Saltiel E. Colistin and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury. J Pharm Pract. 2014 Dec;27(6):554-61.
  • Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy. 2011 Dec;31(12):1257-64.
  • Berg JR, Spilker CM, Lewis SA. Effects of polymyxin B on mammalian urinary bladder. J Membr Biol. 1996 Nov;154(2):119-30.
  • Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009 Jun 15;48(12):1724-8.
  • Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 2014 Apr;43(4):349-52.
  • Rocco M, Montini L, Alessandri E, Venditti M, Laderchi A, De Pascale G, RaponiG, Vitale M, Pietropaoli P, Antonelli M. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care. 2013 Aug 14;17(4)
  • Dewan A, Shoukat M. Evaluation of risk of nephrotoxicity with high dose, extended-interval colistin administration. Indian J Crit Care Med. 2014 Jul;18(7):427-30.
  • Garzotto F, Piccinni P, Cruz D, Gramaticopolo S, Dal Santo M, Aneloni G, Kim JC, Rocco M, Alessandri E, Giunta F, Michetti V, Iannuzzi M, Belluomo Anello C,Brienza N, Carlini M, Pelaia P, Gabbanelli V, Ronco C; NEFROINT investigation group. RIFLE-based data collection/ management system applied to a prospective cohort multicenter Italian study on the epidemiology of acute kidney injury in the intensive care unit. Blood Purif. 2011;31(1-3):159-71.
  • Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram- negative bacterial infections. Int J Antimicrob Agents. 2010 Mar;35(3):297-300.
  • Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M,Weintrob A, Wortmann G. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009 Jun 15;48(12):1724-8.
  • Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect. 2011 Feb;62(2):187-90.
  • Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Oct;54(10):4503-5. Chemother. 2010
  • Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, Conly J. Utilization of colistin for treatment of multidrug- resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol. 2008 Nov;19(6):413-8.
  • Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009Dec;22(6):535-43.
  • Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS.Incidence of and risk factors for colistin- associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011 Nov;53(9):879-84.
  • Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney Int. 2008 Mar;73(5):538-46.

Yoğun Bakım Hastalarında Kolistin Nefrotoksisitesinin Değerlendirilmesi

Yıl 2018, Cilt: 7 Sayı: 1, 10 - 14, 01.01.2018

Fatma Kaplan Efe Fatma Ayerden Ebinç Serdar Karakaya İbrahim Karadağ Murat Eser Oktay Ünsal Aysun Aybal Kutlugün Esin Beyan

https://doi.org/10.5505/abantmedj.2018.39306

Öz

GİRİŞ ve AMAÇ: Bu çalışmanın amacı, Kolistin verilen hastalarda nefrotoksisite gelişiminin ve bunu etkileyen faktörlerin değerlendirilmesidir. YÖNTEM ve GEREÇLER: Kolistin verilen 51 hasta nefrotoksiste gelişen ve gelişmeyenler olarak iki gruba ayrıldı. Gruplar, demografik özellikler ve laboratuar verileri yönünden karşılaştırıldı.BULGULAR: Hastaların %64,7’sinde kolistine bağlı nefrotoksisite saptandı. Nefrotoksisite gelişen hastaların ölüm oranı daha yüksek bulundu p: 0,01 .TARTIŞMA ve SONUÇ: Yoğun bakım hastalarında kolistin nefrotoksisitesine dikkat edilmelidir.

Anahtar Kelimeler

Kolistin nefrotoksisite yoğun bakım

Kaynakça

  • Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005 May 1;40(9):1333-41.
  • Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther.2012 Aug;10(8):917-34.
  • Pike M, Saltiel E. Colistin and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury. J Pharm Pract. 2014 Dec;27(6):554-61.
  • Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy. 2011 Dec;31(12):1257-64.
  • Berg JR, Spilker CM, Lewis SA. Effects of polymyxin B on mammalian urinary bladder. J Membr Biol. 1996 Nov;154(2):119-30.
  • Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009 Jun 15;48(12):1724-8.
  • Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 2014 Apr;43(4):349-52.
  • Rocco M, Montini L, Alessandri E, Venditti M, Laderchi A, De Pascale G, RaponiG, Vitale M, Pietropaoli P, Antonelli M. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care. 2013 Aug 14;17(4)
  • Dewan A, Shoukat M. Evaluation of risk of nephrotoxicity with high dose, extended-interval colistin administration. Indian J Crit Care Med. 2014 Jul;18(7):427-30.
  • Garzotto F, Piccinni P, Cruz D, Gramaticopolo S, Dal Santo M, Aneloni G, Kim JC, Rocco M, Alessandri E, Giunta F, Michetti V, Iannuzzi M, Belluomo Anello C,Brienza N, Carlini M, Pelaia P, Gabbanelli V, Ronco C; NEFROINT investigation group. RIFLE-based data collection/ management system applied to a prospective cohort multicenter Italian study on the epidemiology of acute kidney injury in the intensive care unit. Blood Purif. 2011;31(1-3):159-71.
  • Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram- negative bacterial infections. Int J Antimicrob Agents. 2010 Mar;35(3):297-300.
  • Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M,Weintrob A, Wortmann G. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009 Jun 15;48(12):1724-8.
  • Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect. 2011 Feb;62(2):187-90.
  • Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Oct;54(10):4503-5. Chemother. 2010
  • Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, Conly J. Utilization of colistin for treatment of multidrug- resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol. 2008 Nov;19(6):413-8.
  • Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009Dec;22(6):535-43.
  • Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS.Incidence of and risk factors for colistin- associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011 Nov;53(9):879-84.
  • Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney Int. 2008 Mar;73(5):538-46.
Toplam 18 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Research Article
Yazarlar

Fatma Kaplan Efe Bu kişi benim

Fatma Ayerden Ebinç Bu kişi benim

Serdar Karakaya

İbrahim Karadağ Bu kişi benim

Murat Eser Bu kişi benim

Oktay Ünsal Bu kişi benim

Aysun Aybal Kutlugün Bu kişi benim

Esin Beyan Bu kişi benim

Yayımlanma Tarihi 1 Ocak 2018
Yayımlandığı Sayı Yıl 2018 Cilt: 7 Sayı: 1

Kaynak Göster

APA Efe, F. K., Ebinç, F. A., Karakaya, S., Karadağ, İ., vd. (2018). Yoğun Bakım Hastalarında Kolistin Nefrotoksisitesinin Değerlendirilmesi. Abant Medical Journal, 7(1), 10-14. https://doi.org/10.5505/abantmedj.2018.39306
AMA Efe FK, Ebinç FA, Karakaya S, Karadağ İ, Eser M, Ünsal O, Kutlugün AA, Beyan E. Yoğun Bakım Hastalarında Kolistin Nefrotoksisitesinin Değerlendirilmesi. Abant Med J. Ocak 2018;7(1):10-14. doi:10.5505/abantmedj.2018.39306
Chicago Efe, Fatma Kaplan, Fatma Ayerden Ebinç, Serdar Karakaya, İbrahim Karadağ, Murat Eser, Oktay Ünsal, Aysun Aybal Kutlugün, ve Esin Beyan. “Yoğun Bakım Hastalarında Kolistin Nefrotoksisitesinin Değerlendirilmesi”. Abant Medical Journal 7, sy. 1 (Ocak 2018): 10-14. https://doi.org/10.5505/abantmedj.2018.39306.
EndNote Efe FK, Ebinç FA, Karakaya S, Karadağ İ, Eser M, Ünsal O, Kutlugün AA, Beyan E (01 Ocak 2018) Yoğun Bakım Hastalarında Kolistin Nefrotoksisitesinin Değerlendirilmesi. Abant Medical Journal 7 1 10–14.
IEEE F. K. Efe, “Yoğun Bakım Hastalarında Kolistin Nefrotoksisitesinin Değerlendirilmesi”, Abant Med J, c. 7, sy. 1, ss. 10–14, 2018, doi: 10.5505/abantmedj.2018.39306.
ISNAD Efe, Fatma Kaplan vd. “Yoğun Bakım Hastalarında Kolistin Nefrotoksisitesinin Değerlendirilmesi”. Abant Medical Journal 7/1 (Ocak 2018), 10-14. https://doi.org/10.5505/abantmedj.2018.39306.
JAMA Efe FK, Ebinç FA, Karakaya S, Karadağ İ, Eser M, Ünsal O, Kutlugün AA, Beyan E. Yoğun Bakım Hastalarında Kolistin Nefrotoksisitesinin Değerlendirilmesi. Abant Med J. 2018;7:10–14.
MLA Efe, Fatma Kaplan vd. “Yoğun Bakım Hastalarında Kolistin Nefrotoksisitesinin Değerlendirilmesi”. Abant Medical Journal, c. 7, sy. 1, 2018, ss. 10-14, doi:10.5505/abantmedj.2018.39306.
Vancouver Efe FK, Ebinç FA, Karakaya S, Karadağ İ, Eser M, Ünsal O, Kutlugün AA, Beyan E. Yoğun Bakım Hastalarında Kolistin Nefrotoksisitesinin Değerlendirilmesi. Abant Med J. 2018;7(1):10-4.